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Celiac disease (CD) is a common autoimmune disorder induced by ingestion of
gluten in genetically susceptible individuals. Despite the prerequisite for a genetic
predisposition, only a minority of the 40% of the Caucasian population that has this
genetic predisposition develops the disease. Thus, environmental and/or lifestyle factors
play a causal role in the development of CD. The incidence of CD has increased over
the last half-century, resulting in rising interest in identifying risk factors for CD to enable
primary prevention. Early infant feeding practices have been suggested as one of the
factors influencing the risk of CD in genetically susceptible individuals. However, recent
large prospective studies have shown that neither the timing of gluten introduction
nor the duration or maintenance of breastfeeding influence the risk of CD. Also, other
environmental influences have been investigated as potential risk factors, but have not
led to primary prevention strategies. Secondary prevention is possible through early
diagnosis and treatment. Since CD is significantly underdiagnosed and a large proportion
of CD patients are asymptomatic at the time of diagnosis, secondary prevention will not
identify all CD patients, as long as mass screening has not been introduced. As following
a gluten-free diet is a major challenge, tertiary prevention strategies are discussed as well.
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INTRODUCTION
The incidence and prevalence of celiac disease (CD) have risen over time; this is, in part, due to
the current awareness in combination with the advent of highly sensitive and specific serological
tests, but it also reflects a true increase in the prevalence of CD (1, 2). The clinical presentation of
CD has changed dramatically in the last decades. Patients with atypical or non-specific symptoms
often report a delay in diagnosis of CD that may last for years (3) or even worse, CD remains
unrecognized and, therefore, untreated (4–6). Untreated disease is associated with long-term
complications, such as chronic anemia, delayed puberty, neuropsychiatric disturbances, associated
autoimmune disorders, infertility, small-for-date-births, osteoporosis, and, rarely, malignancy and
it can reduce the quality of life (7–9). Treatment with a gluten-free diet (GFD) reduces the burden
of morbidity and mortality associated with untreated CD. Thus, prevention would be beneficial
(10). Prevention is defined as any activity that reduces the burden of mortality or morbidity from
disease, taking place at the primary, secondary, or tertiary level (11) (Table 1). The purpose of this
review is to present the current knowledge of the preventive strategies for CD (Table 2).
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Theoretically, CD could be prevented by avoiding gluten
introduction into the feeding of infants genetically predisposed to
CD. However, this is not a realistic strategy, because the strongest
genetic predisposing factors for CD, HLA DQ2 and/or HLA-
DQ8, are present in about 40% of the Caucasian population. In
addition, most of these individuals do not develop CD, since the
prevalence of CD is ∼1%. Another reason why avoiding gluten
ingestion by a large part of the population is not desirable is that
gluten-containing cereals (among others wheat, barley and rye)
are important sources of dietary iron, fiber, calcium, folate, and
vitamin B12 (12, 13).
Much knowledge about the possible relationship between
infant feeding practices and the development of CD has been
obtained from “The Swedish epidemic of CD” during the mid-
1980s. Between 1985 and 1987, the incidence of CD in Swedish
children younger than 2 years of age increased 4-fold, followed by
a rapid decline in its incidence around 1995 (14). The occurrence
of the epidemic was related to new dietary recommendations:
delaying the introduction of all gluten-containing foods to
infants until 6 months of age and changes in breastfeeding
practices. In Sweden, the incidence of CD diminished when
earlier introduction of gluten (>4 months) was reintroduced
(14). Many retrospective studies have investigated this hypothesis
that delayed introduction of gluten leads to CD with conflicting
results. Results of observational studies suggested the existence
of a “window of opportunity” for primary prevention, by
introducing gluten between 4 and 6 months of age to reduce
the risk of CD (Table 3). This and other early feeding practices,
such as breastfeeding and breastfeeding at the time of gluten
introduction, have been investigated as primary prevention
strategies for reducing the risk of CD as well (Tables 4, 5). A
systemic review and meta-analysis, which included all of the
studies published on this topic between 1966 and 2004, found
that breastfed children had a 52% reduction in the risk of being
affected by CD compared to those who were not breastfed during
the time of gluten introduction (pooled OR 0.48; 95% CI: 0.40 to
0.59) (37). However, all of these studies were observational and
retrospective.
Among the prospective studies that have been published, there
are two gluten interventional ones, namely PREVENTCD and
CELIPREV (15, 16) (Table 3):
• PREVENTCD is a multinational, randomized, double-blind,
placebo-controlled dietary interventional study involving 944
children who had at least 1 first-degree relative with CD
and HLA-DQ2 and/or DQ8. From age 4 to 6 months,
475 participants received 100mg of vital gluten daily and
469 received placebo. After 24 weeks, intake of gluten
was liberalized in both groups. CD serology was measured
periodically. Children with elevated levels of CD antibodies
and/or with symptoms suggestive of CD were offered small
bowel biopsies to confirm the diagnosis. The results showed
no significant difference between the groups receiving the early
gluten intervention or placebo in the risk of developing CD at
the age of 3 years.
• CELIPREV is an Italian multicenter, randomized,
interventional study that compared early (at 6 months
of age; n = 297) and delayed (at 12 months of age; n =
256) introduction of gluten into the diet of infants at risk
for CD (first-degree relative with CD; HLA-DQ2 and/or
DQ8 positivity). The results showed a reduced risk of
developing CD by the age of 2 years in those with delayed
introduction to gluten at 12 months, but no difference
between groups in the risk of developing CD at 5 years of
age.
A few of the large, prospective, observational cohort
(non-interventional) studies assessing the relationship
between infant feeding practices and the risk of CD
and/or CD autoimmunity (CDA) pointed out the following
(Tables 3–5):
• The Generation R cohort study, including 1679 genetically
susceptible CD children from the general population
of Rotterdam, the Netherlands, showed that neither
breastfeeding for 6 months or longer nor later exposure
to gluten (>6 months) compared to earlier exposure
(<6 months) was significantly associated with CDA (21).
• The Norwegian Mother and Child Cohort Study (MoBa)
showed that breastfeeding longer than 12 months was
associated with a higher risk of CD (22). However, this cohort
only considered children with clinically diagnosed CD, so
probably missed an important proportion of the children with
CD.
• The BABYDIAB, a German cohort study, found no association
between the duration of breastfeeding nor gluten introduction
before or after 3 months of age and risk of CDA (26).
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TABLE 3 | Evidence of the effect of the timing of gluten introduction into the diet
of young children and the risk of celiac disease.
First author, year, study Conclusion
INTERVENTIONAL STUDIES
Vriezinga et al. (15),
PREVENTCD
No significant difference in CD
development at 3 years for gluten
introduction at 4 vs. 6 months∧
Lionetti et al. (16),
CELIPREV
No significant difference in CD
development at 5 years for gluten
introduction at 6 vs. 12 months
Sellitto et al. (17) No significant difference in CDA* risk for
gluten introduction at 6 vs. 12 months
Hummel et al. (18)/Beyerlein
et al. (19)**
No significant difference in CD and CDA
for different gluten introduction at 6 vs.
12 months
PROSPECTIVE COHORT STUDIES
Andrén Aronsson et al. (20),
TEDDY
No significant difference in CD and CDA
for gluten introduction at <17 vs. 17–26
vs. >26 weeks
Jansen et al. (21),
Generation R
No significant difference in CDA for gluten
introduction at <6 vs. >6 months
Størdal et al. (22), MoBa Borderline significant difference in CD
development at gluten introduction <6 vs.
>6 months
Welander et al. (23), ABIS No significant difference in CD for different
times of gluten introduction from 0 to
12 months
Norris et al. (24), DAISY Significantly more CD with gluten
introduction <3 or >7 months vs. gluten
introduction between 4 and 6 months.
Ziegler et al. (25),
BABYDIAB
No significant difference in CD for gluten
introduction ≤3 vs. >6 months
Hummel et al. (26),
BABYDIAB
No significant difference in CDA for gluten
introduction <3 vs. >3 months
RETROSPECTIVE STUDIES
Ivarsson et al. (27) Significantly more CD with gluten
introduction >6 months compared to
gluten introduction between 4 and
6 months.
Peters et al. (28) No significant difference in CD gluten
introduction at ≤3 vs. >3 months
Falth-Magnusson et al. (29) No significant difference in CD for different
times of gluten introduction
CROSS-SECTIONAL STUDY
Ivarsson et al. (30), ETICS Significantly more CD with gluten
introduction >6 months compared to
gluten introduction between 4 and
6 months.




• The Environmental Determinants of Diabetes in the Young
(TEDDY) project is an observational, prospective, cohort
study that followed children at genetic risk for type 1
diabetes, wherein development of CD is a secondary outcome.
The TEDDY study included 6,403 children with a genetic
predisposition to developing CD in the United States,
Finland, Germany, and Sweden. The study found that gluten
TABLE 4 | Most important studies on the evidence of protection from celiac
disease with breastfeeding.
First author, year, study Conclusion
INTERVENTIONAL STUDIES
Vriezinga et al. (15), PREVENTCD No effect
Lionetti et al. (16), CELIPREV No effect
PROSPECTIVE STUDIES
Jansen et al. (21), Generation R No effect
Størdal et al. (22), MoBa No effect*
Welander et al. (23), ABIS No effect
Norris et al. (24), DAISY study No effect




Decker et al. (31) No effect
Roberts et al. (32) No effect
Ivarsson et al. (27) Protective
Peters et al. (28) Protective
Greco et al. (33) Protective
Ascher et al. (34) No effect
Falth-Magnusson et al. (29) Protective
Auricchio et al. (35) Protective
CROSS-SECTIONAL STUDY
Ivarsson et al. (30), ETICS Protective
*Breastfeeding (BF) > 1 year predisposing; **Same population.
TABLE 5 | Evidence of the effect of breastfeeding at the time of gluten
introduction and risk for celiac disease.
First author, year, study Conclusion
INTERVENTIONAL STUDIES
Vriezinga et al. (15), PREVENTCD No effect
Lionetti et al. (16), CELIPREV No effect
PROSPECTIVE COHORT STUDIES
Andrén Aronsson et al. (36), TEDDY No effect
Størdal et al. (22), MoBa No effect
Hummel et al. (26), BABYDIAB No effect
Norris et al. (24), DAISY No effect
RETROSPECTIVE STUDIES
Ivarsson et al. (27) Protective
Peters et al. (28) Protective
Ascher et al. (34) No effect
Falth-Magnusson et al. (29) Protective
introduction before 17 weeks of age or later than 26 weeks of
age was not associated with an increased risk for CDA or CD;
however, continuation of breastfeeding more than 1 month
after gluten introduction compared with discontinuation of
breastfeeding prior to gluten introduction was associated with
increased risk of CDA but not of CD (20).
Two systematic reviews and meta-analyses, which included
the above prospective interventional studies and large cohort
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studies (Tables 3–5), concluded that the timing of gluten
introduction and the duration or maintenance of breastfeeding
do not influence the development of CD (38, 39).
Interest in the quantity of gluten at introduction into the diet
of infants was also raised based on the results of the Swedish
CD epidemic. The evaluation of results of one retrospective
observational study indicated that large amounts of gluten (>16
g/day) at the time of first introduction increased the risk of
CD (27). The same group of investigators further compared, in
the ETIC project, 2 populations born in 1993 and 1997; they
found a lower risk of CD in the population born in 1997 who
ingested significantly less gluten-containing cereal compared to
the population born in 1993 (24 vs. 38 g/day intake, respectively,
under the age of 2 years) (30). Also, the Swedish case control
study from the TEDDY cohort, in which gluten intake was
assessed by dietary questionnaires, found that a high intake (>5.0
g/day) of gluten during the first 2 years of life was associated
with an increased risk of CD (36). However, a similar analysis
of the data in the international PREVENTCD study showed that
the amount of gluten consumed at 11–36 months of age did not
influence the risk for CD development (40). Thus, the influence
of the amount of gluten intake on CD risk remains a topic of
discussion.
In accordance with the results from the above-mentioned
studies, ESPGHAN has updated its guidelines for gluten
introduction into the diet of young children. The current
recommendation no longer suggests introducing gluten between
4 and 6 months of age; rather they recommend that gluten may
be introduced into the infant’s diet anytime between 4 and 12
completed months of age, since gluten introduction in these
infants does not seem to influence the absolute risk of developing
CDA or CD during childhood (38).
In addition to gluten and breastfeeding, other environmental
factors may be involved in the risk and/or prevention of CD.
Identifying and influencing these factors may lead to preventive
strategies. Some of these factors are discussed below.
(Intestinal) Infections
Intestinal infections might change gut permeability and lead
to the passage of immunogenic gluten peptides through the
epithelial barrier, and thus, activate an autoimmune reaction.
Many groups have studied the relationship between infections,
both viral and bacterial, and the risk of CD, with varying
results (Table 6). The role of early infections was retrospectively
explored in the Swedish population-based incident case referent
ETICS study. Having three or more parental-reported infections,
regardless of the type of infection, during the first 6 months of life
was associated with significantly increased risk of CD, even after
adjusting for infant feeding and socioeconomic status (61).
Results of prospective studies are contradictory. Data from
the PREVENTCD study showed no significant difference in
the cumulative incidence of CD between children with and
without parental-reported gastrointestinal infections in the first
18 months of life (15). However, the TEDDY study found
that parental-reported early gastrointestinal infections increased
the risk of CDA within the following 3 months (HR 1.33;
95% CI 1.11–1.59). This effect was observed particularly in
TABLE 6 | Some of the most relevant studies# on infections and the risk of celiac
disease or celiac disease autoimmunity.
First author, year, study Pathogen Association
between CD(A)
PROSPECTIVE STUDIES
Stene et al. (41) Rotavirus Positive
Thevenot et al. (42) Hepatitis C virus None
Gravina et al. (43) Hepatitis C virus None
Jansen et al. (44) EBV, CMV and HSV-1 Negative
Karhus et al. (45) Influenza None
Dore et al. (46) Helicobacter Pylori None
RETROSPECTIVE STUDIES
Lahdeaho et al. (47) Adenovirus 12/40 Positive
Vesy et al. (48) Adenovirus 12, CMV, HSV None




Mahon et al. (50) Adenovirus 12 None
Fine et al. (51) Hepatitis C virus Positive
Carlsson et al. (52) Enterovirus None*
Villalta et al. (53) Hepatitis C virus Positive
Ruggeri et al. (54) Hepatitis C virus Positive
Sarmiento et al. (55) Enterovirus, EBV, CMV,
Hepatitis C virus
Positive
Tjernberg and Ludvigsson (56) RSV Positive
Abid et al. (57) Hepatitis B virus Positive
Tarish et al. (58) Adenovirus None
Alaedini et al. (59) Borrelia None
Bouziat et al. (60) Reovirus Positive
CD, celiac disease; CDA, celiac disease autoimmunity; EBV, Epstein Barr virus; CMV,
cytomegalovirus; HSV, herpes simplex virus; RSV, respiratory syncytial virus.
#Case reports were excluded.
*Between these infection during pregnancy and CD development in the offspring.
those children with non-HLA-DQ2 genotypes who had been
breastfed for <4 months, as well as in children born in winter
and introduced to gluten before the age of 6 months (62).
In the prospective MoBa study, children with ≥10 infections
(respiratory and gastrointestinal) before 18 months of age had
a higher risk of being clinically diagnosed with CD compared
with children who had ≤4 infections, even after adjustments for
antibiotic exposure (63). Viral infections have been suggested to
play a role in the development of CD (Table 9), and recently,
reovirus has been reported as a trigger for the disease, both in
vitro as well as in vivo (60). In vitro, reovirus infection induced
a disruption of intestinal immune homeostasis and initiated
loss of oral tolerance and T-helper inflammatory immunity to
dietary antigens. In CD patients anti-Reovirus antibodies were
significantly overrepresented in comparison to health controls.
However, this disruption of the immune homeostasis may not
be exclusive to reovirus and their role in the development of CD
should be studied prospectively.
Type of Delivery
The mode of delivery (vaginal or cesarean section [C-section])
has a strong influence on shaping the initial gut microbiota
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TABLE 7 | Some of the most relevant studies on type of delivery and the risk for
celiac disease.
First author, year, study Conclusion
Koletzko et al. (73), TEDDY No association with CDA or CD
Dydensborg Sander et al. (74),
ETICS
No association with CD
Lionetti et al. (72), CELIPREV No association with CD
Kristensen and Henriksen (68) Positive association between emergency CS
and CD
Emilsson et al. (70), MoBa No association between CS and CD
Sevelsted et al. (71) No association with CD
Marild et al. (69) Positive association with CD
Decker et al. (31) Positive association with CD
Roberts et al. (32) Negative association between CS and CD
CD, celiac disease; CDA, celiac disease autoimmunity; CS, cesarean section.
composition. It has been hypothesized that infants born by C-
section acquire different bacterial communities compared to
vaginally delivered infants (64), which may influence the short-
and long-term immune responses to environmental factors,
thereby predisposing to autoimmunity (65). Also, the type of
C-section, emergency vs. elective, has been hypothesized as
a different possible influencing factor, since the cord blood
immune cell phenotypes are affected by stress during vaginal
delivery and this does not happen by elective C-section (66).
In addition, infants born vaginally and during emergency C-
section are colonized at first by fecal and vaginal bacteria of
the mother, whereas infants born through elective cesarean
delivery are exposed initially to bacteria originating from the
hospital environment and healthcare workers. Infants born by
cesarean delivery are characterized by a more slowly diversifying
microbiota, with a substantial absence of Bifidobacteria species
and Bacteroides and the presence of facultative anaerobes, such
as Clostridium species. These differences might influence the
development of the mucosal immune system, the establishment
of a stable intestinal host-microbial homeostasis, as well as the
mucosal barrier function and ultimately contribute to the risk
of acquiring immune-mediated diseases, such as CD, later in life
(67).
Some studies have identified C-section as a risk factor
for the development of CD (68, 69). However, more recent
prospective studies have found no association (70–73) (Table 7).
Recently, a large, observational, register-based, cohort study
investigated the association between the type of delivery and the
risk of developing CD in two independent population cohorts
(Denmark, birth cohort 1995–2010 and Norway, birth cohort
2004–2012) (74). A total of 3,314 children were diagnosed with
CD. C-sections were performed in 286,640 children, and the
mode of delivery was not associated with an increased risk of
diagnosed CD.
In the above-mentioned Danish cohort, the association
between elective C-section and diagnosed CD was positive and
reached borderline statistical significance after adjusting for year
of birth, sex, maternal age, education, parity, gestational age,
and weight for gestational age (OR: 1.20; 95% CI: 1.00–1.43).
However, this finding was not replicated in the corresponding
Norwegian cohort (OR: 0.96; 95% CI: 0.79–1.17) (74). Analysis of
the data from the Swedish Medical Birth Register between 1973
and 2008, comparing cases with villous atrophy with age- and
sex-matched controls from the general population, found a weak
association between an elective C-section and CD in offspring
(adjusted odds ratio [OR] = 1.15), but no increased risk for
CD diagnoses after an emergency (adjusted OR = 1.02) or any
C-section (adjusted OR = 1.06) (69). Data from a population-
and national register-based cohort including all children born
in Denmark from January 1997 to December 2012 showed the
opposite: children delivered by emergency C-section were at an
increased risk for CD (adjusted OR = 1.22), whereas children
delivered by elective C-section were not (adjusted OR = 0.69)
(68). Thus, despite the plausible hypothesis that mode of delivery
affects risk of CD, the current literature showed no association
between the type of delivery and the risk of CD (Table 7).
Antibiotics
The ETIC study found no evidence of increased CD risk with
antibiotic use in the first 6 months of life (61). However, other 2
retrospective studies have shown a positive association between
antibiotic use and CD risk (75, 76). A recent analysis of the
TEDDY study showed that cumulative exposure to β-lactam or
macrolide antibiotics, up to 6 months, during the first or second
year of life andwithin 6months before the seroconversion period,
was not associated with CDA. Also, maternal use of antibiotics
during pregnancy was also evaluated as a risk factor and did not
significantly contribute to CDA risk in this study. In conclusion,
the role of antibiotics in the development of CD is a topic that
remains unclear and requires more research.
Microbiota
CD development has also been linked to alterations in the human
gut microbiome, which is necessary for proper development
of the immune system and establishment of oral tolerance
in early life (65). The contributing role of perturbations
in the gut microbiota, and of specific enteric bacteria, to
gluten-induced immunopathology has been shown in animal
models (77). PROFICEL, a prospective study of 164 healthy
Spanish newborns with a first-degree relative with CD and
HLA-DQ2 and/or DQ8 positivity, reported an association
between the HLA-DQ genotype and the intestinal microbiota
composition. In this study, the HLA-DQ2/8 genotype and
the type of feeding (breastfeeding or formula) were shown
to influence, in conjunction, the composition of the intestinal
microbiota (78). The high-risk genotype for developing CD
(HLA-DQ2, including homozygous HLA-DQ2.5 or heterozygous
DQ2.5/DQ2.2 and DQ2.2/DQ7.5) was associated with reduced
numbers of Bifidobacterium, specifically of the species B.
Longum, compared to the rest of the lower-risk genotypes (79).
Also, other studies have found similar results; the duodenal and
fecal microbiota of CD patients is unbalanced, with decreased
numbers of anti-inflammatory bacteria, such as Bifidobacterium
spp. and increased numbers of Bacteroides spp., which are only
partially normalized after a long-term gluten free diet (GFD)
(80–82). In a double-blind, randomized, placebo-controlled,
interventional trial performed in children with newly diagnosed
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CD, children were randomized to receive Bifidobacterium longum
or placebo in conjunction with a GFD (83). A decrease in both the
numbers of the Bacteroides fragilis group and the fecal secretory
IgA concentration was found, which might further confirm the
role of microbiota in the pathogenesis of CD. But, so far, studies
have failed to find a distinct microbiota profile in patients with
CD.
A sub-study of the PROFICEL project, including 10CD cases
and 10 matched controls, suggests altered early proportions
of Firmicutes and members of the Actinobacteria phylum
(B. Longum) in children who later progressed to CD
(84). Hopefully, the results of the Celiac Disease Genomic,
Environmental, Microbiome, and Metabolomic (CDGEMM)
study, a multicenter, longitudinal study of infants at risk for CD,
will provide an answer to the question regarding the role of the
gut microbiome and the risk of CD (85). CDGEMM aims to
enroll 500 infants aged 0–6 months with a first-degree family
member with CD. Health status, anthropometrics, nutritional
information, household and environmental information,
and blood and stool samples are being collected regularly to
understand the role of the gut microbiome as an additional
factor that may play a key role in early steps involved in the
development of autoimmune disease (85).
In conclusion, in the field of primary prevention, infant
feeding practices have been explored by interventional studies
with long-term follow up, but have shown no protection for risk
of CD. Other possible influences on the development of CD,
especially the role of infections and the gut microbiome, need
further research.
Text box
Summary of evidence of effectiveness of possible




Breastfeeding at the time of gluten introduction No effect
Timing of gluten introduction No effect
Amount of gluten at the time of gluten introduction Unclear
(Intestinal) infections Unclear





Secondary prevention focuses on early detection and treatment
(Table 8). Active case finding refers to the liberal diagnostic
testing of subjects with CD-associated symptoms. In the general
population, this approach has led to the early diagnosis of
many patients, resulting in significant health improvement after
treatment, good compliance with the GFD, and good CD-related
quality of life (86, 87); unfortunately, however, it does not
counter the entire under-diagnosis of CD (88, 89). Only a small
proportion of the undiagnosed patients are detected with this
TABLE 8 | Secondary prevention strategies for celiac disease.
Case finding
Screening in high-risk groups
First-degree relatives of CD patients
Type 1 diabetes mellitus
Autoimmune thyroid disease
Autoimmune liver disease




strategy, since∼50% of the children in screening-detected studies
have symptoms at the time of diagnosis (15, 16, 90).
Screening for Celiac Disease in High-risk
Groups
Because of the high prevalence of CD among these groups,
evidence-based guidelines recommend screening for early
detection of the disease (7) (Table 8). A plethora of studies are
available on 2 of the populations who belong to these high-
risk groups, namely first-degree relative of patients with CD and
children with type 1 diabetes mellitus (T1DM).
First-degree Relatives of CD Patients
Many studies have demonstrated that first-degree relatives
(FDRs) of celiac patients have a higher risk of developing CD
than the general population, with a prevalence ranging from 1.6
to 38% (91). Based on a systematic review and meta-analysis,
Sing et al. (91) reported that the pooled prevalence of CD was
7.5% in 10,252 FDRs (91). The risk of developing CD among
FDRs is influenced by gender and HLA haplotype (15, 16). CD
occurs more often in girls (female: male ratio of 2–3:1), and HLA-
DQ2 homozygous children have a significantly higher risk of
developing CD than HLADQ2 heterozygous children (14.9 vs.
3.9%, respectively, at the age of 3 years) (15).
Children With Conditions/Diseases Associated With
CD
The prevalence of CD in patients with T1DM has been reported
by most studies as ranging between 4 and 10% (92). Many
children with T1DM and CD are asymptomatic or at least
symptoms of CD have not been observed. In these cases, CDmay
only be detected by serologic screening. However, it has been
shown that strict adherence to a GFD was <30% in children
with both CD and T1DM, compared to 81% among patients
with CD only (93). Maintaining a strict GFD in addition to
a diabetic diet requires additional time, effort, and expense.
Evidence is inconclusive as to whether the benefits of screening
and potentially treating asymptomatic individuals outweigh the
harms of managing a population already burdened with a serious
illness. The Celiac Disease and Diabetes-Dietary Intervention
and Evaluation Trial (CD-DIET) (ClinicalTrials.gov Identifier:
NCT01566110) involves screening of children and adults with
T1DM for asymptomatic CD, followed by randomization to a
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GFD or no-GFD group, to assess outcomes (including diabetes
control, bone mineral density, and health-related quality of
life) over 1 year to clarify effects of screening and treating
asymptomatic CD in this population with a GFD (94).
Mass Screening
Screening the general population, also called mass screening,
would theoretically be the best form of secondary prevention
since it could potentially detect all cases of CD, including those
in asymptomatic patients as well as those in patients who lack
symptoms. Results from most screening studies performed in
the general population suggest that symptoms are not reliable
predictors of CD (15, 95, 96), reinforcing the place of mass
screening as the best strategy for secondary prevention of CD
enabling early treatment to reduce the burden of morbidity and
mortality associated with untreated CD (97, 98).
However, mass screening for CD is still debated, partly
because evidence has been lacking on the accuracy of diagnostic
tests and on the health benefits after diagnosis and treatment
of asymptomatic detected patients. This uncertainty also affects
the cost benefit of mass screening, which is needed for
implementation of mass screening for CD (99, 100). Most studies
on the diagnostic accuracy of diagnostic tests for CD have
been conducted in symptomatic patients (101, 102). Because the
positive predictive value declines when the test is used in settings
with a low pre-test prevalence, such as the general population, the
sensitivity and specificity of these tests are lower in the setting of
mass screening.
Recently, a prospective study performed in Rotterdam has
shown a positive predictive value of 81% for CD in the
general pediatric population (96). These authors also showed
that undiagnosed CD is associated with a lower body mass
index compared to controls at the age of 9 years (96) and
associated with fetal growth restriction and lower birth and
placental weight during pregnancy (8). Additional information
about the importance and effectiveness of screening comes from
a population-based-screening study performed in Sweden; this
study showed that at 10 years of age, children with CD detected
by screening already had reduced bone mineral density in the
total body and spine compared with age-matched controls. These
differences were not found in children with CD on a GFD from 3
years of age, indicating that children with screening-detected CD
benefit from early diagnosis and treatment (103).
The data on the benefits and harms of screening are limited.
Only one randomized trial evaluated the effectiveness of GFD
vs. no GFD in apparently asymptomatic adults with screen-
detected CD and found that initiation of a GFD in screen-
detected adults with unrecognized symptoms was associated with
improved gastrointestinal symptoms (104).
Other traditional reason against mass screening are that
adherence to the GFD in minimally or asymptomatic patients
would be lower than in symptomatic patients and that the
quality of life is decreased in screening-detected CD patients
following a GFD. However, 10 years of follow up among
Dutch children and the results of a sub-study from the ETICS
project showed similar adherence rates to the GFD in screening-
detected children compared with clinically detected children
(105, 106). No significant differences in health-related quality
of life (HRQoL) were observed between screening-detected and
symptom-detected adult patients (107, 108). Furthermore, a
systematic review and meta-analysis on dietary adherence and
HRQoL in adult patients with CD detected by screening showed
a significantly lower HRQoL after 1 year of treatment with
a GFD in symptom-detected patients compared to screening-
detected patients (109). Despite the aforementioned literature
that is positive about screening of the general population, the
current literature recommending mass screening is limited.
TERTIARY PREVENTION
Gluten-free Diet (GFD)
Tertiary prevention focuses on reducing the impact of existing
disease by improved treatment (Table 9). One of these strategies
involves optimizing adherence to the GFD. Complete removal
of gluten from the diet is a challenge, as gluten is present in a
wide variety of foods. However, since the introduction of allergen
labeling in the European Union (EU) in 2005, gluten cannot be
hidden in products. The amount of gluten capable of initiating
an antigenic reaction has been estimated to be >20 mg/kg (or
parts per million = ppm) of gluten, and contamination below
20 ppm is considered safe over a wide range of foods in daily
consumption.
Improving Monitoring of and Adherence to
the GFD
Dietitian
Due to the complexity of the GFD, it is essential that newly
diagnosed patients be referred to a dietitian with expertise in
CD. A delay in referral, or no referral at all, increases the
likelihood of the patient obtaining inaccurate information from
the Internet, health food stores, alternative health practitioners,
family, friends, and other sources, often resulting in confusion,
frustration, and insufficient knowledge regarding CD and the
GFD (110).
Gluten-containing cereals, such as wheat, barley, and rye, are
important sources of dietary iron, calcium, folate, and vitamin
B12. As the treatment of CD with a GFD can lead to nutritional
deficiencies, the support of a dietitian is necessary to avoid these
deficiencies. Also, consultation with someone with knowledge in
TABLE 9 | Tertiary prevention strategies for celiac disease.
Strategy Successful
Optimal adherence to the GFD Yes




Aspergillus niger prolyl endoprotease (AN-PEP) Unclear
Desensitization therapy (therapeutic vaccine) Unknown
CD, celiac disease; GFD, gluten-free diet.
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the field of replacement (gluten-free) products, such as amaranth,
buckwheat, quinoa, sorghum and teff, is of great importance and
could improve intakes of protein, iron, calcium, and fiber by
patients with CD (111).
Validated Food Questionnaires
A dietary interview to assess compliance with the GFD is the
best way to detect errors in GFD adherences among children and
young adults, but it is timue-consuming (20–30min per patient)
and requires expert personnel. Several short questionnaires have
been developed to measure GFD adherence in order to save
time, and while some are not sensitive enough, others are useful
in assessing compliance to the diet (112). With the increasing
use of self-assessment and alternative follow-up methods for
CD patients, including electronic patient records and E-health
tolls, completing questionnaires before or during a medical
consultation should be easily implemented in the healthcare of
children and young adults with CD (113).
Measurement of Gluten Immunogenic Peptides
(GIPs)
Available methods to assess GFD compliance are time-
consuming and are also insufficiently sensitive to detect
occasional dietary transgressions that may cause gut mucosal
damage. Determination of serum TG2A is usually used during
the follow-up of a patient on a GFD, as this marker improves
with gluten elimination (114). However, it has been reported
that even while following a GFD, children and women with CD
have a much higher prevalence of gastrointestinal symptoms
than controls, and they also use healthcare services more often
(115). As mucosal damage may still persist without TG2A,
antibody testing may be negative in patients with only partial
adherence to the GFD (116). Therefore, it is necessary to have
a non-invasive biomarker to monitor compliance with the GFD.
Certain GIPs are resistant to gastrointestinal digestion and can
interact with the immune system of patients with CD to trigger
an autoimmune response against transglutaminase and other
antigens. A proportional fraction of the GIPs absorbed in the
gastrointestinal tract make it to the circulation and are excreted
in urine. GIPs are detectable in concentrated urines and may
be useful in clinical practice as a monitoring tool to follow-up
compliance with the GFD. GIPs are detected in urine samples
6–48 h after gluten intake (>25mg) and remained detectable for
1–2 days (117).
Treatment Options for CD Other Than the
GFD
Several other treatments aimed at different pathogenic targets
of CD have been studied in recent years: modification of
gluten to produce non-immunogenic gluten, endoluminal
therapies to degrade gluten in the intestinal lumen, increasing
gluten tolerance, modulation of intestinal permeability, and
regulation of the adaptive immune response. However, not all
of these therapies have been tested in clinical trials (yet). The
most advanced studies are devoted to larazotide acetate and
prolyl-endopeptidases degrading toxic gluten peptides and to
therapeutic vaccination.
Larazotide Acetate
Patients with active CD have increased intestinal permeability.
Zonulin, a modulator of epithelial tight junctions, is
overexpressed in these patients. Release of zonulin in response
to binding between gliadin peptides and a specific chemokine
receptor (CXCR3) results in a measurable reduction in the usual
intestinal barrier and allows enhanced passage of gliadin. This
mechanism has been the target of advanced research that led to
the development of larazotide acetate (AT-1001), an octapeptide
that inhibits gliadin-induced intestinal permeability. Several
phase I and II clinical trials have confirmed the safety of this agent
and suggest a potential beneficial effect of larazotide (118, 119).
Additionally, patients who were treated with larazotide acetate
had significantly fewer symptoms (patient reported Celiac
Disease Gastrointestinal System Rating Score) compared with
those taking a placebo (120–122). A dose-response effect was
not seen, with the most benefit encountered at the lowest
(0.5mg) of 4 dosages administered (121); however, this study
did not measure histologic endpoints, and larazotide had no
significant effect on serologic levels of specific CD antibodies as
TG2A.
Endopeptidases
The gluten peptides, which are responsible for inducing the
immunological response in CD patients, are rich in proline and
are highly resistant to enzymatic proteolysis within the digestive
tract. For many years, there have been studies conducted to
investigate the effectiveness of orally administered prolyl oligo-
peptidases in the degradation of toxic gliadin peptides before they
reach the mucosa of the small intestine.
Latiglutenase (ALV003, Alvine Pharmaceuticals, San Carlos,
CA, USA) is an orally administered mixture of 2 recombinant
gluten-specific proteases—a cysteine protease (EP-B2) and a
prolyl endopeptidase (PEP)—which have been shown in vitro
to degrade gluten (123). Both endopeptidases are active and
stable at gastric pH (124). In a Phase 2 study with ALV003,
adults with biopsy-proven CD were randomly assigned to groups
receiving ALV003 or placebo, together with a daily 2 g gluten
challenge. Upper endoscopy was performed at baseline and after
the gluten challenge. Primary endpoint included the villus height
to crypt depth ratio and CD3+ intra-epithelial lymphocytes (IEL)
density. Serologic markers and symptoms were also assessed.
In the ALV003 group, there were no changes in histological
measures, while in the placebo group, evidence of mucosal injury
was shown after gluten challenge. In contrast, no differences were
seen in symptoms and serologic markers of CD in both groups.
In a phase 2 study involving patients with symptomatic CD
and histologic evidence of significant duodenal mucosal injury,
ALV003 did not improve histologic and symptom scores when
compared with placebo (125). However, a subgroup-analysis
of the study showed a statistically significant, dose-dependent
reduction in the severity and frequency of symptoms in
seropositive but not in seronegative patients (126).
Aspergillus niger prolyl endoprotease (AN-PEP; DSM,
Heerlen, The Netherlands) is also an endopeptidase, isolated
from the fungus Aspergillus niger. The enzyme is active between
a pH of 2 and 8, with an optimum activity at pH 4–5, thus, in
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the stomach and small intestine (127). In a randomized, placebo-
controlled, crossover study, 18 self-reported gluten-sensitive
subjects consumed a porridge containing 0.5 g gluten together
with two tablets containing either a high or low dose of AN-
PEP or placebo. Gastric and duodenal contents were sampled
over 180min. The primary outcome was defined as the efficacy
of the high dose of AN-PEP compared with placebo in degrading
at least 50% of gluten, based on the amount of gluten detected
in the duodenum. The researchers concluded that the AN-PEP
enzyme is effective in degrading small amounts of gluten as part
of a complexmeal in the stomach, but it is not intended to replace
a GFD in patients with gluten-related disease (128). In a Phase
2a double-blinded, placebo-controlled, randomized trial, 16 CD
patients on a GFD, who were in serological and histopathological
clinical remission, were administered AN-PEP or a placebo with
gluten-containing toast (∼7 g/day gluten). The mean score for
the gastrointestinal subcategory of the CD quality (CDQ) was
relatively high throughout the study, indicating that AN-PEP was
well-tolerated. In the efficacy phase, the CDQ scores of patients
consuming gluten with placebo or gluten with AN-PEP did not
significantly deteriorate and, moreover, no differences between
the groups were observed.
Larazotide and PEPs will not become an alternative to the




NexVax2 from ImmusanT is a desensitizing vaccine that uses
three dominant gluten peptides administered subcutaneously
to induce an immune response in CD patients who carry
the immune recognition gene HLA-DQ2.5, which accounts
for disease in 80–90% of patients. The aim of the vaccine
is to use peptide-based immunotherapy to shift the T-
cell response from pro-inflammatory to regulatory, in
order to restore immune tolerance to gluten. Phase 1b
clinical trials of this vaccine have recently been completed
supporting the safety, tolerability and relevant bioactivity of
Nexvax2 (129).
CONCLUSIONS
• Celiac disease is a common autoimmune disorder induced by
ingestion of gluten in genetically susceptible individuals.
• Only a minority of those who are at genetic risk develop the
disease.
• The incidence of CD has increased over the last half-century,
resulting in rising interest in identifying risk factors for CD to
enable prevention.
• Environmental and/or lifestyle factors play a causal role in the
development of CD.
• For primary prevention (i.e., interventions before CD occurs),
early feeding practices seem to have no impact on the risk
of developing CD during childhood. Other environmental
influences have been investigated as potential risk factors;
however, they have not yet led to primary prevention
strategies.
• Secondary prevention is possible through early diagnosis and
treatment; however, it will not identify all CD patients as long
as mass screening has not been introduced.
• As a gluten-free diet is a major challenge, tertiary
prevention strategies are under evaluation; however,
none of these measures are currently recommended as
treatment.
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